Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Goals
Fat LossMuscle BuildingInjury HealingAnti-AgingCognitive EnhancementSleep OptimizationImmune SupportGut HealingSkin RejuvenationSexual Health
Peptides
Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PNC-27
Cancer Research
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 32
Back to Home

Peptide Comparison

TesamorelinvsCJC-1295 with DAC

The only FDA-approved peptide specifically designed to melt away stubborn belly fat by telling your brain to release more growth hormone naturally—working with your body's own systems rather than replacing them.

Long-acting growth hormone releaser that works around the clock to boost your body's natural GH production with just one or two injections per week.

Growth HormoneGrowth Hormone

At a Glance

Quick
comparison

Dose Range

Tesamorelin

1–2 mg

CJC-1295 with DAC

1000–2000 mcg

Frequency

Tesamorelin

Once daily

CJC-1295 with DAC

Twice weekly

Administration

Tesamorelin

Subcutaneous injection

CJC-1295 with DAC

Subcutaneous injection

Cycle Length

Tesamorelin

12+ weeks

CJC-1295 with DAC

8-12 weeks

Onset Speed

Tesamorelin

Moderate (1-2 weeks)

CJC-1295 with DAC

Moderate (1-2 weeks)

Evidence Level

Tesamorelin

Strong human trials (Phase 3 or FDA approved)

CJC-1295 with DAC

Moderate human trials (Phase 1-2)

Efficacy

Benefit
ratings

Tesamorelin
CJC-1295 with DAC

Visceral Fat Reduction

Tesamorelin96%
CJC-1295 with DAC0%

Metabolic Health

Tesamorelin89%
CJC-1295 with DAC0%

Natural GH Boost

Tesamorelin92%
CJC-1295 with DAC0%

GH Elevation

Tesamorelin0%
CJC-1295 with DAC92%

Convenience

Tesamorelin0%
CJC-1295 with DAC95%

Recovery Support

Tesamorelin0%
CJC-1295 with DAC88%

Technical Data

Compound
specifications

Tesamorelin

Molecular Formula

C221H366N72O67S

Molecular Weight

5135.86 g/mol

Half-Life

26-38 minutes

Bioavailability

~100% (subcutaneous injection)

CAS Number

218949-48-5

CJC-1295 with DAC

Molecular Formula

C165H269N47O46

Molecular Weight

3647.28 g/mol

Half-Life

6-8 days

Bioavailability

~100% (subcutaneous)

CAS Number

863288-34-0

Protocols

Dosing
tiers

Tesamorelin

starting

1 mg

Once daily

2-4 weeks

Some practitioners start at the lower approved dose to assess tolerance before increasing. The standard FDA-approved dose is 2mg, but starting lower allows you to monitor for side effects like injection site reactions or joint discomfort.

standard

2 mg (or 1.4 mg Egrifta SV)

Once daily

26 weeks or longer

This is the FDA-approved dose shown effective in large Phase 3 trials. Clinical studies showed significant visceral fat reduction at 26 weeks with continued benefits at 52 weeks. Note: Egrifta SV uses a 1.4mg dose which is bioequivalent to the original 2mg formulation.

advanced

2 mg

Once daily

52+ weeks

Long-term use beyond the initial 26 weeks has been studied and shows maintained benefits. However, stopping treatment causes visceral fat to return. Many users continue indefinitely with periodic monitoring. Extended use requires regular IGF-1 and glucose monitoring.

CJC-1295 with DAC

starting

1000 mcg (1 mg)

Once weekly

2-4 weeks

Start with once weekly dosing to assess tolerance and gauge your individual response to the peptide before increasing.

standard

1000-2000 mcg (1-2 mg)

Twice weekly

8-12 weeks

The most common protocol used in research and practice. Provides sustained GH elevation throughout the week with the long half-life.

advanced

2000 mcg (2 mg)

Twice weekly

12+ weeks

Higher dosing for maximum GH stimulation. Monitor for side effects like water retention and adjust as needed. Extended cycles require periodic breaks.

Applications

Best
suited for

Tesamorelin

People with Stubborn Visceral Fat

If you carry your weight around your midsection—the deep belly fat that wraps around your organs—tesamorelin is specifically designed for you. Unlike weight loss drugs, it targets visceral fat while preserving the normal subcutaneous fat that's healthy to have.

HIV Patients with Lipodystrophy

Tesamorelin is FDA-approved specifically for HIV-associated lipodystrophy—the abnormal fat accumulation in the belly that antiretroviral medications can cause. It's the only treatment proven to help this condition, reducing both the physical and psychological burden.

Those Concerned About Metabolic Health

Visceral fat isn't just cosmetic—it's metabolically dangerous, linked to heart disease, diabetes, and inflammation. By reducing visceral fat, tesamorelin also improves triglycerides, cholesterol ratios, and may help protect your liver from fatty liver disease.

Adults Wanting Natural GH Stimulation

Unlike synthetic growth hormone injections, tesamorelin works WITH your body's natural systems. It tells your pituitary to release more of YOUR OWN growth hormone, maintaining normal feedback loops and reducing the risks associated with supraphysiological GH levels.

CJC-1295 with DAC

Growth Hormone Optimization

CJC-1295 with DAC excels at providing a sustained, steady elevation of growth hormone levels. Unlike shorter-acting peptides that create brief spikes, the DAC modification keeps GH elevated for days, mimicking a more youthful hormone profile.

Muscle Building and Recovery

By increasing both GH and IGF-1 levels, this peptide supports protein synthesis and muscle repair. Users often notice improved recovery between workouts and better ability to build and maintain lean muscle mass.

Anti-Aging and Longevity

Growth hormone naturally declines with age, contributing to many signs of aging. CJC-1295 with DAC helps restore more youthful GH levels, potentially supporting better skin quality, energy levels, and overall vitality.

Body Composition Improvement

The combination of increased GH and IGF-1 promotes fat metabolism while preserving muscle tissue. Many users experience gradual fat loss, particularly in stubborn areas, while maintaining or building lean mass.

Convenient Weekly Dosing

Unlike peptides requiring daily or twice-daily injections, the extended half-life of CJC-1295 with DAC means just one or two injections per week provide continuous benefits. Ideal for those who want results without daily protocols.

Safety Profile

Side
effects

Tesamorelin

Common

  • Injection site reactions
  • Joint pain (arthralgia)
  • Muscle pain (myalgia)
  • Peripheral edema

Uncommon

  • Carpal tunnel symptoms
  • Elevated blood glucose

Serious

  • Severe allergic reaction
  • Worsening diabetes

CJC-1295 with DAC

Common

  • Injection site reactions
  • Water retention
  • Flushing
  • Tingling sensation

Uncommon

  • Headaches
  • Fatigue or lethargy
  • Joint discomfort

Serious

  • Carpal tunnel symptoms
  • Blood glucose elevation

Research Status

Safety
& evidence

Tesamorelin

Evidence Level

Strong human trials (Phase 3 or FDA approved)

FDA Status

FDA approved for other use

Safety Overview

Tesamorelin has a strong safety profile backed by FDA approval and multiple large Phase 3 clinical trials involving over 800 patients. The most common issues are injection site reactions and the typical side effects of elevated growth hormone (joint pain, fluid retention). Glucose metabolism should be monitored as some patients experience increased blood sugar. Long-term cardiovascular safety data is still being collected, which is why the FDA recommends reassessing treatment if visceral fat doesn't reduce.

Contraindications

  • xActive malignancy or history of cancer (pituitary tumors especially)
  • xKnown hypersensitivity to tesamorelin or mannitol
  • xPregnancy
  • xDisruption of the hypothalamic-pituitary axis from conditions like hypophysectomy or pituitary tumor surgery

CJC-1295 with DAC

Evidence Level

Moderate human trials (Phase 1-2)

FDA Status

Research compound

Safety Overview

CJC-1295 with DAC was evaluated in Phase 1-2 human clinical trials where it demonstrated a generally favorable safety profile. The most common adverse events were mild injection site reactions including temporary pain, swelling, and redness. No serious adverse events were reported in the published clinical studies. The compound was being developed for HIV-associated lipodystrophy before the program was discontinued.

Contraindications

  • xActive cancer or history of malignancy
  • xPregnancy or breastfeeding
  • xPituitary tumors or disorders
  • xDiabetic retinopathy
  • xUncontrolled diabetes

Decision Guide

Which is
right for you?

Choose Tesamorelin if...

  • Reducing visceral abdominal fat
  • Improving metabolic health markers
  • Supporting natural growth hormone production
  • Addressing HIV-associated lipodystrophy

Choose CJC-1295 with DAC if...

  • Boosting natural growth hormone production
  • Building lean muscle mass
  • Improving body composition
  • Anti-aging and longevity
Peptide ProTesamorelin vs CJC-1295 with DAC — Peptide Comparison | Peptide Initiative